Otulfi (Ustekinumab)

Ustekinumab is a monoclonal antibody that binds to the p40 subunit shared by interleukin‑12 and interleukin‑23. By blocking these cytokines, it suppresses the Th1 and Th17 immune responses that drive inflammation in psoriasis, psoriatic arthritis, and Crohn’s disease, leading to symptom relief.

The dosing regimen for Otulfi is determined by the prescribing physician based on the specific indication, patient weight, and clinical response. Typical regimens involve an initial loading dose followed by maintenance injections, but exact amounts and intervals are individualized and should follow the prescriber’s instructions.

Data on ustekinumab use in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To order Otulfi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and required import documentation.

The primary alternative class for these indications includes tumor necrosis factor‑alpha (TNF‑α) inhibitors such as adalimumab or infliximab. Compared with TNF‑α blockers, ustekinumab targets a different cytokine pathway (IL‑12/23), which may offer efficacy in patients who have inadequate response to TNF‑α inhibitors and may have a distinct safety profile regarding infection risk.

Otulfi must be stored refrigerated at 2‑8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. If the product reaches room temperature, it may be used for a limited period as specified in the product labeling, after which any remaining solution should be discarded.

Otulfi is supplied as a sterile solution for subcutaneous injection. The injection is typically performed by a healthcare professional in a clinical setting, using the recommended needle size and injection technique. Patients may be taught self‑administration after appropriate training, following the prescriber’s instructions.

Serious risks include severe infections such as tuberculosis or opportunistic infections, potential development of malignancies (e.g., lymphoma, skin cancers), hypersensitivity reactions including anaphylaxis, and possible cardiovascular events. Patients should be monitored regularly for signs of infection, new or worsening symptoms, and any unexpected adverse events.

Otulfi is contraindicated in patients with known hypersensitivity to ustekinumab or any component of the formulation. It should also be avoided in individuals with active, untreated infections, including tuberculosis, and in those receiving live vaccines. Caution is advised for patients with a history of malignancy or severe heart disease.